Atlas Trials

A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

Clinical trial NCT05104788 · RECRUITING

Trial details

NCT number
NCT05104788
Sponsor
Peking University Cancer Hospital & Institute
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Non-Small Cell Lung Cancer
Start date
2021-10-25
Primary completion
2024-03-01
Enrollment
27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.